Cargando…

The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China

Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zhouyuan, Liu, Ke, Zhang, Yuting, Hong, Qingyu, Sun, Liyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371820/
https://www.ncbi.nlm.nih.gov/pubmed/36017019
http://dx.doi.org/10.1155/2022/8977011
_version_ 1784767243673927680
author Peng, Zhouyuan
Liu, Ke
Zhang, Yuting
Hong, Qingyu
Sun, Liyuan
author_facet Peng, Zhouyuan
Liu, Ke
Zhang, Yuting
Hong, Qingyu
Sun, Liyuan
author_sort Peng, Zhouyuan
collection PubMed
description Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and examined its properties. This methodological study was conducted at a tumor hospital located in southwestern China. Patients with cervical cancer who had been reexamined in the outpatient department of the hospital and hospitalized from June to August 2019 were selected. The item analysis, exploratory factor analysis (EFA), and reliability analysis were tested. The relationships between benefit finding and sociodemographic and disease-related variables were analyzed by ANOVA and regression models. A total of 247 patients were assessed (mean age: 48.0 ± 13.3 years). Educational level, self-perceived disease severity, and physical exercise were the predictors of benefit finding. The correlation coefficient between 22 items and their dimensions was the best. EFA analysis supported a five-factor model for structure validity. All Cronbach's alpha for the Chinese version of the BFS (BFS-C) was greater than 0.80. The results demonstrated the good reliability and validity of BFS-C. It appears to be a useful scale to assess experience of benefit finding among patients with cervical cancer in China.
format Online
Article
Text
id pubmed-9371820
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93718202022-08-24 The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China Peng, Zhouyuan Liu, Ke Zhang, Yuting Hong, Qingyu Sun, Liyuan Contrast Media Mol Imaging Research Article Recently, the Benefit Finding Scale (BFS) has been translated and culturally adapted for use in China. However, further validation of the instrument is required before it can be used in the management of patients with cervical cancer in China. In this study, we conducted the questionnaire survey and examined its properties. This methodological study was conducted at a tumor hospital located in southwestern China. Patients with cervical cancer who had been reexamined in the outpatient department of the hospital and hospitalized from June to August 2019 were selected. The item analysis, exploratory factor analysis (EFA), and reliability analysis were tested. The relationships between benefit finding and sociodemographic and disease-related variables were analyzed by ANOVA and regression models. A total of 247 patients were assessed (mean age: 48.0 ± 13.3 years). Educational level, self-perceived disease severity, and physical exercise were the predictors of benefit finding. The correlation coefficient between 22 items and their dimensions was the best. EFA analysis supported a five-factor model for structure validity. All Cronbach's alpha for the Chinese version of the BFS (BFS-C) was greater than 0.80. The results demonstrated the good reliability and validity of BFS-C. It appears to be a useful scale to assess experience of benefit finding among patients with cervical cancer in China. Hindawi 2022-08-04 /pmc/articles/PMC9371820/ /pubmed/36017019 http://dx.doi.org/10.1155/2022/8977011 Text en Copyright © 2022 Zhouyuan Peng et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Peng, Zhouyuan
Liu, Ke
Zhang, Yuting
Hong, Qingyu
Sun, Liyuan
The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
title The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
title_full The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
title_fullStr The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
title_full_unstemmed The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
title_short The 22-Item Benefit Finding Scale: Validation and Application among Patients with Cervical Cancer in Ethnic Minority Areas of Southwestern China
title_sort 22-item benefit finding scale: validation and application among patients with cervical cancer in ethnic minority areas of southwestern china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371820/
https://www.ncbi.nlm.nih.gov/pubmed/36017019
http://dx.doi.org/10.1155/2022/8977011
work_keys_str_mv AT pengzhouyuan the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT liuke the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT zhangyuting the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT hongqingyu the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT sunliyuan the22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT pengzhouyuan 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT liuke 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT zhangyuting 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT hongqingyu 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina
AT sunliyuan 22itembenefitfindingscalevalidationandapplicationamongpatientswithcervicalcancerinethnicminorityareasofsouthwesternchina